Displaying 51 - 75 of 600
Real-time RT-PCR for quantitative detection of t(9;22) BCR-ABL1 fusion transcripts that result in major p210 (E13, E14) or minor p190 (E1) fusion proteins with option to add p230 detection (micro or atypical variant). p230 testing may be ordered as…
Molecular
Probes: ABL1 (9q34); ASS1 (9q34; BCR (22q11.2) Disease(s): CML, ALL, MPN Note: For suspected ALL, STAT processing is available by request. Note STAT along with MD contact name and phone number to receive STAT results.
FISH
Ber-EP4 recognizes two glycoproteins of 34 and 49 kDa present on the surface and the cytoplasm of all epithelial cells except the superficial layers of squamous epithelial, hepatocytes and parietal cells. It does not label mesothelial cells and…
Immunohistochemistry (IHC)
Beta-catenin is an important regulator of cell–cell adhesion and embryogenesis. Mutations of beta-catenin could lead to some human cancers. Normal cells show membrane staining for beta-catenin, while cytoplasmic and/or nuclear staining is abnormal.…
Immunohistochemistry (IHC)
This antibody is specific for the Lewis Y (Type 2 Chain) carbohydrate antigen. Lewis Y has been evaluated as a clinical marker for the diagnosis and prognosis of cholangiocarcinoma, hepatocellular carcinoma and breast cancer. It was also shown that…
Immunohistochemistry (IHC)
Probes: BIRC3(API2)/MALT1 t(11;18) Disease(s): MALT lymphoma, NHL
FISH
Probes: +3 (Cen 3) | +7 (Cen 7) | p16 (9p21) | +17 (Cen 17) Disease(s): Bladder cancer
FISH
BOB1 is present in all B-cells expressing Ig. The combination of BOB1 and OCT2 staining is helpful in distinguishing between classical Hodgkin lymphoma (at least one marker negative) and nodular lymphocyte predominant Hodgkin lymphoma or T-cell…
Immunohistochemistry (IHC)
Testing is performed by Fulgent Genetics. Patient and physician or genetic counselor signatures on the Fulgent Genetics Informed Consent for Genetic Testing form are required. Testing will be put on hold until signatures are received. A complete…
Molecular
Bi-directional sequencing of exon 15 of the BRAF gene, which includes qualitative detection of V600 mutations E, K, D, and others, plus other significant exon 15 mutations.  For solid tumors, tumor enrichment is performed before extraction. Expanded…
Molecular
Probes: BRAF (7q34) Disease(s): Brain cancer, thyroid cancer, melanoma
FISH
A monoclonal antibody (VE1) against mutant BRAF (V600E) permits fast assessment of the mutant protein expression throughout a tumor sample in hairy cell leukemia, some melanomas, and some thyroid carcinomas. BRAF mutation is a strong molecular…
Immunohistochemistry (IHC)
The Brain Tumor NGS Fusion Panel is an RNA-based next-generation sequencing panel that detects translocations and fusions with known and novel fusion partners of these genes: ALK, BRAF, C11orf95, EGFR, EGFRvIII, EML4, ETV6, FGFR1, FGFR2, FGFR3, MET…
Molecular
BRCA1 (breast and ovarian cancer susceptibility protein 1) is a nuclear phosphoprotein that plays a role in maintaining genomic stability and acts as a tumor suppressor. This test detects expression of BRCA1 protein and is not intended to identify…
Immunohistochemistry (IHC)
Testing is performed by Fulgent Genetics. Patient and physician or genetic counselor signatures on the Fulgent Genetics Informed Consent for Genetic Testing form are required. Testing will be put on hold until signatures are received. A complete…
Molecular
Testing is performed by Fulgent Genetics. Patient and physician or genetic counselor signatures on the Fulgent Genetics Informed Consent for Genetic Testing form are required. Testing will be put on hold until signatures are received. A complete…
Molecular
BRCA1 and BRCA2 mutation analysis is performed by next-generation sequencing of all coding exons of the BRCA1 and BRCA2 genes to detect point mutations and small insertions/deletions. This test does not detect large deletions or duplications. This…
Molecular
Testing is performed by Fulgent Genetics. Patient and physician or genetic counselor signatures on the Fulgent Genetics Informed Consent for Genetic Testing form are required. Testing will be put on hold until signatures are received. A complete…
Molecular
Breast Cancer Index (BCI) is an RT-PCR assay performed on FFPE breast tumor tissue that integrates two gene expression-based biomarkers: 1) the HOXB13:IL17BR ratio (H/I), which is associated with tumor responsiveness to endocrine therapy; and 2)…
Molecular
The Breast NGS Fusion Panel is an RNA-based next-generation sequencing panel that detects translocations and fusions with known and novel fusion partners of these genes: ACTL6A, AKT3, BRAF, CAPZA2, CCDC170 , CCDC6, COA5, CTNNBL1, ESR1, ETV5, FGFR3,…
Molecular
The combination of CK5 + P63 + CK8/18 (Breast Triple Stain) can be useful in distinguishing ductal carcinoma in situ (DCIS) from microinvasive breast carcinoma. This multiplex can decipher between a radial scar and infiltrating carcinoma. P63 (…
Immunohistochemistry (IHC)
BRG1 (SMARCA4) is involved in chromatin remodeling, which regulates the binding of transcription factors to DNA. Immunhistochemical loss of expression of BRG-1 (SMARCA4) is associated with the diagnosis of small cell carcinoma of ovary,…
Immunohistochemistry (IHC)
Concurrent bi-directional sequencing of hotpost regions in the BTK and PLC-gamma-2 genes. Analysis includes the BTK mutation C481S and surrounding regions corresponding to amino acids C464 to M509 and the following PLC-gamma-2 mutations and…
Molecular
Concurrent analysis of the following by bi-directional sequencing: CARD11 exons 5 and 6, CD79B exon 5 including common Y196 mutations, CXCR4 C-terminus region, and MYD88 exon 5 including the L265P mutation.
Molecular
Bi-directional sequencing to detect the C481S mutation in exon 15 and other potential mutations within the amino acid range C464 to M509. Testing is available separately or in combination with PLC-gamma-2 in the BTK Inhibitor Acquired Resistance…
Molecular